Animal cell culture is the in vitro maintenance and proliferation of animal cells outside the living organism under controlled laboratory conditions, provided with appropriate nutrients, temperature, pH, and osmolality. It involves the isolation of cells from animal tissues, surgical removal of organs, and their placement into an artificial environment to enhance survival and growth.
The establishment of animal cell culture as a routine laboratory technique accelerated in the 1950s with the creation of the first human cell line.
Historical Limitation: Early biological research was constrained by the finite lifespan of primary cells isolated from tissues, which underwent senescence and died after a limited number of divisions.
Discovery of Immortal Cells (HeLa): In 1951, George Gey established the first continuous human cell line, HeLa, derived from a cervical cancer biopsy of an African-American patient named Henrietta Lacks. These cells possessed the unique ability to divide indefinitely, providing a standardized, immortal model system that revolutionized polio vaccine testing, radiation research, and molecular genetics.
| Investigator(s) | Year | Breakthrough Contribution |
|---|---|---|
| Sydney Ringer | 1882 | Developed a balanced salt solution mimicking body fluids to maintain beating frog hearts ex vivo. |
| Roux | 1885 | Maintained the medullary plate of a chick embryo in warm saline. |
| Jolly | 1903 | Demonstrated in vitro cell survival and division of salamander leucocytes. |
| Ross Harrison | 1907 | Published experiments showing frog embryo nerve fiber growth in vitro using the hanging drop method. |
| Lewis and Lewis | 1911 | Cultured connective tissue cells and demonstrated heart muscle contractility; formulated the first liquid media containing sea water, serum, embryo extracts, salts, and peptides. |
| Alexis Carrel | 1912 | Introduced aseptic techniques to tissue culture and utilized trypsin and embryo extracts/serum. |
| Rous and Jones | 1913-1940 | Introduced antibiotics (penicillin/streptomycin), laminar air-flow cabinets (1916), and trypsinization to produce homogenous cell suspensions (1940). |
| Katherine Sanford et al. | 1940s-50s | First to clone mouse L-cells; demonstrated that tumor cells give rise to continuous cell lines. |
| Margaret Gey & George Gey | 1948 | Observed contact inhibition among fibroblasts, initiating quantitative cell culture. |
| Abercrombie & Heaysma | 1952 | Cultured polio virus in human E-cells, enabling large-scale polio vaccine production. |
| Enders et al. | 1954 | Established human cell lines for human and veterinary vaccine manufacturing. |
| Hayflick & Moorhead | 1955-1961 | Described the finite lifespan of normal human diploid cells (the Hayflick limit) and published methods for maintaining tumor-derived differentiated cells. |
| Harry Eagle | 1962-1970 | Developed chemically defined media (MEM) and described attachment factors and feeder layers. |
| Buonassisi et al. | 1962 | Studied the differentiation of normal myoblasts in vitro. |
| Littlefield | 1964 | Developed HAT selection for hybridoma screening. |
| David Yaffe | 1968 | Isolated and cultured human fetal lung fibroblasts. |
| Kohler & Milstein | 1975 | Produced the first hybridoma capable of secreting monoclonal antibodies. |
The selection of an appropriate growth medium is the most critical stage in cell culture, determined by the specific cell type and experimental objectives (e.g., growth, differentiation, or recombinant protein production).
| Category | Type | Description | Advantages / Disadvantages |
|---|---|---|---|
| Natural Media | Coagulant, Tissue Extracts, Biological Fluids | Plasma clots, embryo extracts (chicken), serum, lymph, amniotic fluid. | Provides natural growth factors / Poor reproducibility, undefined composition. |
| Synthetic Media | Serum-containing | Basal media supplemented with human, bovine, or equine serum. | Promotes cell attachment and growth / High batch-to-batch variation, risk of contamination. |
| Synthetic Media | Serum-free | Basal media supplemented with crude protein fractions (e.g., bovine serum albumin). | Selective for specific cell types / Requires unique formulations for different cell lines. |
| Synthetic Media | Xeno-free | Contains human-source components; completely free of animal-derived additives. | Eliminates animal pathogens / Expensive, human-derived components still vary. |
| Synthetic Media | Protein-free | Contains only non-protein, undefined peptide fractions (protein hydrolysates). | Facilitates downstream purification / May require adaptation of cells. |
| Synthetic Media | Chemically defined (Basal) | Completely defined inorganic salt solutions (e.g., PBS, DPBS, HBSS, EBSS). | Maintains pH, osmotic pressure, and membrane potential / Lacks growth-promoting factors. |
| Synthetic Media | Complex Media | Highly enriched formulations (e.g., EMEM, DMEM, RPMI-1640, Ham's F-12). | Supports high-density growth and specialized cell lines / Complex and expensive. |
Serum is a complex mixture of proteins, growth factors, hormones, and lipids that serves as a universal supplement for animal cell growth.
To support optimal cell survival and proliferation, the physical environment must mimic the homeostatic conditions of the host organism.
| Property | Finite Cell Lines | Continuous Cell Lines |
|---|---|---|
| Lifespan | Limited number of cell divisions (undergoes senescence). | Infinite division potential (immortalized). |
| Origin | Derived from normal, healthy diploid tissues. | Derived from tumor tissues or induced via transformation. |
| Growth Rate | Slow to moderate. | Rapid; high growth density. |
| Anchorage Dependency | Strictly anchorage-dependent (adherent). | Often anchorage-independent (can grow in suspension). |
| Tumorigenicity | Non-tumorigenic. | Highly tumorigenic. |
When adherent cells reach confluence (covering the entire available substrate surface), they must be sub-cultured to prevent overcrowding and cell death.
Cell viability assays are performed to determine the proportion of living cells in a culture, evaluate drug/toxin efficacy, or monitor culture health.
Animal cell culture serves as a foundational platform for modern biotechnology, virology, and pharmaceutical manufacturing.
| Therapeutic Protein | Host Cell Line Used | Clinical Application / Indication |
|---|---|---|
| Follicle Stimulating Hormone (FSH) | CHO cells | Infertility treatment |
| Human Growth Hormone (HGH) | CHO cells | Growth Hormone deficiency |
| Erythropoietin (EPO) | CHO cells | Anemia (associated with chemotherapy or chronic renal failure) |
| Factor VIII | CHO cells | Hemophilia A (classical bleeding disorder) |
| Factor IX | CHO cells | Hemophilia B (Christmas disease) |
| Interleukin 2 (IL-2) | CHO cells | Cancer immunotherapy |
| Tissue Plasminogen Activator (tPA) | CHO cells | Thrombolytic therapy for acute stroke and myocardial infarction |
| Monoclonal Antibodies (mAbs) | Hybridoma cells | Targeted cancer therapy and autoimmune diseases |
Wild-Type Molecular Limitation: Traditional thrombolytic treatments relied on systemic anticoagulants or bacterial enzymes (like streptokinase) that carried high risks of systemic bleeding and immunogenic reactions.
Engineering Methodology & Recombinant Production of tPA: Tissue Plasminogen Activator (tPA) was the first therapeutic drug produced via mammalian cell culture. The human tPA gene is inserted into a plasmid vector and transfected into CHO cells. The recombinant cells are scaled up in large-scale bioreactors/fermenters. The secreted tPA—a serine protease—is harvested and purified. It selectively binds to fibrin in blood clots and catalyzes the conversion of inactive plasminogen to active plasmin, dissolving the clot locally and minimizing systemic side effects.